Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Nasopharyngeal Airway in Hypotonia Primary and study completion pushed from Oct 2026 to Oct 2028 University of MichiganNot applicable NCT06614582
  2. Notable: Transcutaneous Spinal Cord Stimulation Combined With Arm Bike for Cardiovascular Recovery in SCI Primary completion pushed from Dec 1, 2026 to Dec 1, 2028 University of WashingtonNot applicable NCT06313515
  3. Notable: ACC017 Tablets Compared With Dolutegravir Sodium Tablets · Human Immunodeficiency Virus Type 1 (HIV-1) Phase changed: Phase 1/2 → Phase 3 Jiangsu Aidea Pharmaceutical Group Co., Ltd.Phase 3 NCT07711223
  4. Notable: DNL952 · Late-Onset Pompe Disease Phase changed: Phase 1 → Phase 1/2 Denali Therapeutics Inc.Phase 1/2 NCT07354724
  5. Notable: Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Phase changed: Phase 2 → Phase 1/2 SanofiPhase 1/2 NCT07756957
  6. Notable: XH-S003 Capsules · Paroxysmal Nocturnal Hemoglobinuria (PNH) Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Phase 2 NCT06978699
  7. Notable: Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation Phase changed: Phase 2/3 → Phase 3 Mayo ClinicPhase 3 NCT07487818
  8. Notable: IMPACT-MACS · Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Phase changed: Not applicable → Phase 4 University of Texas Southwestern Medical CenterPhase 4 NCT07361874
  9. Notable: Multimodal AI-based Region-specific Ablation Planning for Hepatocellular Carcinoma: Model Development, External Validation, and a Multicenter Randomized Trial Phase changed: Not specified → Not applicable Chinese PLA General HospitalNot applicable NCT06798194
  10. Notable: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Recruitment opened Boehringer IngelheimPhase 3 NCT07855900
  11. Notable: Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules · Early-Onset Parkinson's Disease Recruitment opened Hangzhou PhecdaMed Co., Ltd.Phase 3 NCT07741045
  12. Notable: SYNCHRONIZE®-HERA · Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Recruitment opened Boehringer IngelheimPhase 3 NCT07850050
  13. Notable: GC3114B in Adults Aged 65 Years or Older Recruitment opened GC Biopharma CorpPhase 2/3 NCT07883928
  14. Notable: IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis · Chronic Hepatitis B Recruitment opened Beijing Continent Pharmaceutical Co, Ltd.Phase 3 NCT07412236
  15. Notable: ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs Recruitment opened Enliven TherapeuticsPhase 3 NCT07905183
  16. Notable: Continuation Study of Tilrekimig · Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time Recruitment opened PfizerPhase 3 NCT07839884
  17. Notable: Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors Recruitment opened Regeneron PharmaceuticalsPhase 1/2 NCT07863024
  18. Notable: RT023 · Advanced Solid Tumors Recruitment opened Shanghai Ruotuo Biosciences Co., Ltd.Phase 1/2 NCT07797426
  19. Notable: MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) Recruitment opened Imagion Biosystems, Inc.Phase 1/2 NCT07885683
  20. Notable: GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) Recruitment opened Eddingpharm (Zhuhai) Co., Ltd.Phase 1/2 NCT07738341
  21. Notable: Modzatinib (ATI-2138) · Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies Recruitment opened Aclaris Therapeutics, Inc.Phase 2 NCT07935590
  22. Notable: BMS-986511 · Major Depressive Disorder Recruitment opened Bristol-Myers SquibbPhase 2 NCT07772531
  23. Notable: SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer Recruitment opened Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2 NCT07863167
  24. Notable: LY4247147 · Obesity or Overweight Who Are Otherwise Healthy Recruitment opened Eli Lilly and CompanyPhase 1 NCT07915245
  25. Notable: HH-1270 in Healthy Chinese Subjects Recruitment opened Huahui HealthPhase 1 NCT07876440